Effectiveness and tolerability of citalopram for the treatment of depression and anxiety disorders in children and adolescents: An open-label study

Shella Schirman; Sefi Kronenberg; Alan Apter; David Brent; Nadine Melhem; Nimrod Pick; Miri Carmel; Amos Frisch; Abraham Weizman; Doron Gothelf

doi:10.1007/s00702-009-0330-x

Effectiveness and tolerability of citalopram for the treatment of depression and anxiety disorders in children and adolescents: An open-label study

Shella Schirman, Sefi Kronenberg, Alan Apter, David Brent, Nadine Melhem, Nimrod Pick, Miri Carmel, Amos Frisch, Abraham Weizman, Doron Gothelf

Research output: Contribution to journal › Article › peer-review

18 Scopus citations

Abstract

To assess the effectiveness and tolerability of citalopram for the acute treatment of children and adolescents suffering from depression and/or anxiety disorders. As much as 78 outpatients, aged 7-18 years with a diagnosis of depressive and/or anxiety disorder, completed an 8-week open trial with citalopram (20-40 mg/day). Outcome, side effects and suicidality were assessed weekly to bi-weekly using appropriate rating scales. At endpoint 56% of subjects were found to be responders (Clinical Global Impression-Improvement [CGI-I] Scale ≤ 2). Subjects with less severe psychopathology and subjects with anxiety disorders showed a more favorable response. As much as 43% of depressed and 51% of anxious subjects had a 50% or greater reduction in scores on our secondary outcome measures, Children's Depression Rating Scale-Revised (CDRS-R) and Screen for Child Anxiety Related Emotional Disorders (SCARED). Most reported adverse events were mild to moderate and did not affect medication adherence. No increase in suicidality was observed during the study. Citalopram was moderately effective, generally well tolerated and safe for the acute treatment of depressed and anxious children and adolescents.

Original language	English
Pages (from-to)	139-145
Number of pages	7
Journal	Journal of Neural Transmission
Volume	117
Issue number	1
DOIs	https://doi.org/10.1007/s00702-009-0330-x
State	Published - Jan 2010
Externally published	Yes

Bibliographical note

Funding Information:
This study has been approved by the local ethics committee and has therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki. This work was supported by the National Institute for Psychobiology in Israel (Grant No. 2006-2), Adams Super Center for Brain Research (Tel Aviv University), the Klingenstein Third Generation Foundation and a National Alliance for Research and Schizophrenia and Depression (NARSAD) Young Investigator Award (Dr. Melhem), and a NARSAD Distinguished Investigator Award (Dr. Brent).

Funding

This study has been approved by the local ethics committee and has therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki. This work was supported by the National Institute for Psychobiology in Israel (Grant No. 2006-2), Adams Super Center for Brain Research (Tel Aviv University), the Klingenstein Third Generation Foundation and a National Alliance for Research and Schizophrenia and Depression (NARSAD) Young Investigator Award (Dr. Melhem), and a NARSAD Distinguished Investigator Award (Dr. Brent).

Funders	Funder number
National Institute for Psychobiology in Israel	2006-2
Klingenstein Third Generation Foundation
National Alliance for Research on Schizophrenia and Depression
Tel Aviv University

Keywords

Antidepressants
Anxiety disorders
Depression
Mood disorders
Selective serotonin reuptake inhibitors
Suicidality

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00702-009-0330-x

Cite this

Schirman, S., Kronenberg, S., Apter, A., Brent, D., Melhem, N., Pick, N., Carmel, M., Frisch, A., Weizman, A., & Gothelf, D. (2010). Effectiveness and tolerability of citalopram for the treatment of depression and anxiety disorders in children and adolescents: An open-label study. Journal of Neural Transmission, 117(1), 139-145. https://doi.org/10.1007/s00702-009-0330-x

@article{3d63706ffecc453383bcd1134d446825,

title = "Effectiveness and tolerability of citalopram for the treatment of depression and anxiety disorders in children and adolescents: An open-label study",

abstract = "To assess the effectiveness and tolerability of citalopram for the acute treatment of children and adolescents suffering from depression and/or anxiety disorders. As much as 78 outpatients, aged 7-18 years with a diagnosis of depressive and/or anxiety disorder, completed an 8-week open trial with citalopram (20-40 mg/day). Outcome, side effects and suicidality were assessed weekly to bi-weekly using appropriate rating scales. At endpoint 56% of subjects were found to be responders (Clinical Global Impression-Improvement [CGI-I] Scale ≤ 2). Subjects with less severe psychopathology and subjects with anxiety disorders showed a more favorable response. As much as 43% of depressed and 51% of anxious subjects had a 50% or greater reduction in scores on our secondary outcome measures, Children's Depression Rating Scale-Revised (CDRS-R) and Screen for Child Anxiety Related Emotional Disorders (SCARED). Most reported adverse events were mild to moderate and did not affect medication adherence. No increase in suicidality was observed during the study. Citalopram was moderately effective, generally well tolerated and safe for the acute treatment of depressed and anxious children and adolescents.",

keywords = "Antidepressants, Anxiety disorders, Depression, Mood disorders, Selective serotonin reuptake inhibitors, Suicidality",

author = "Shella Schirman and Sefi Kronenberg and Alan Apter and David Brent and Nadine Melhem and Nimrod Pick and Miri Carmel and Amos Frisch and Abraham Weizman and Doron Gothelf",

note = "Funding Information: This study has been approved by the local ethics committee and has therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki. This work was supported by the National Institute for Psychobiology in Israel (Grant No. 2006-2), Adams Super Center for Brain Research (Tel Aviv University), the Klingenstein Third Generation Foundation and a National Alliance for Research and Schizophrenia and Depression (NARSAD) Young Investigator Award (Dr. Melhem), and a NARSAD Distinguished Investigator Award (Dr. Brent). ",

year = "2010",

month = jan,

doi = "10.1007/s00702-009-0330-x",

language = "אנגלית",

volume = "117",

pages = "139--145",

journal = "Journal of Neural Transmission",

issn = "0300-9564",

publisher = "Springer Verlag",

number = "1",

}

Schirman, S, Kronenberg, S, Apter, A, Brent, D, Melhem, N, Pick, N, Carmel, M, Frisch, A, Weizman, A & Gothelf, D 2010, 'Effectiveness and tolerability of citalopram for the treatment of depression and anxiety disorders in children and adolescents: An open-label study', Journal of Neural Transmission, vol. 117, no. 1, pp. 139-145. https://doi.org/10.1007/s00702-009-0330-x

TY - JOUR

T1 - Effectiveness and tolerability of citalopram for the treatment of depression and anxiety disorders in children and adolescents

T2 - An open-label study

AU - Schirman, Shella

AU - Kronenberg, Sefi

AU - Apter, Alan

AU - Brent, David

AU - Melhem, Nadine

AU - Pick, Nimrod

AU - Carmel, Miri

AU - Frisch, Amos

AU - Weizman, Abraham

AU - Gothelf, Doron

N1 - Funding Information: This study has been approved by the local ethics committee and has therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki. This work was supported by the National Institute for Psychobiology in Israel (Grant No. 2006-2), Adams Super Center for Brain Research (Tel Aviv University), the Klingenstein Third Generation Foundation and a National Alliance for Research and Schizophrenia and Depression (NARSAD) Young Investigator Award (Dr. Melhem), and a NARSAD Distinguished Investigator Award (Dr. Brent).

PY - 2010/1

Y1 - 2010/1

N2 - To assess the effectiveness and tolerability of citalopram for the acute treatment of children and adolescents suffering from depression and/or anxiety disorders. As much as 78 outpatients, aged 7-18 years with a diagnosis of depressive and/or anxiety disorder, completed an 8-week open trial with citalopram (20-40 mg/day). Outcome, side effects and suicidality were assessed weekly to bi-weekly using appropriate rating scales. At endpoint 56% of subjects were found to be responders (Clinical Global Impression-Improvement [CGI-I] Scale ≤ 2). Subjects with less severe psychopathology and subjects with anxiety disorders showed a more favorable response. As much as 43% of depressed and 51% of anxious subjects had a 50% or greater reduction in scores on our secondary outcome measures, Children's Depression Rating Scale-Revised (CDRS-R) and Screen for Child Anxiety Related Emotional Disorders (SCARED). Most reported adverse events were mild to moderate and did not affect medication adherence. No increase in suicidality was observed during the study. Citalopram was moderately effective, generally well tolerated and safe for the acute treatment of depressed and anxious children and adolescents.

AB - To assess the effectiveness and tolerability of citalopram for the acute treatment of children and adolescents suffering from depression and/or anxiety disorders. As much as 78 outpatients, aged 7-18 years with a diagnosis of depressive and/or anxiety disorder, completed an 8-week open trial with citalopram (20-40 mg/day). Outcome, side effects and suicidality were assessed weekly to bi-weekly using appropriate rating scales. At endpoint 56% of subjects were found to be responders (Clinical Global Impression-Improvement [CGI-I] Scale ≤ 2). Subjects with less severe psychopathology and subjects with anxiety disorders showed a more favorable response. As much as 43% of depressed and 51% of anxious subjects had a 50% or greater reduction in scores on our secondary outcome measures, Children's Depression Rating Scale-Revised (CDRS-R) and Screen for Child Anxiety Related Emotional Disorders (SCARED). Most reported adverse events were mild to moderate and did not affect medication adherence. No increase in suicidality was observed during the study. Citalopram was moderately effective, generally well tolerated and safe for the acute treatment of depressed and anxious children and adolescents.

KW - Antidepressants

KW - Anxiety disorders

KW - Depression

KW - Mood disorders

KW - Selective serotonin reuptake inhibitors

KW - Suicidality

UR - http://www.scopus.com/inward/record.url?scp=76949095648&partnerID=8YFLogxK

U2 - 10.1007/s00702-009-0330-x

DO - 10.1007/s00702-009-0330-x

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 19851705

AN - SCOPUS:76949095648

SN - 0300-9564

VL - 117

SP - 139

EP - 145

JO - Journal of Neural Transmission

JF - Journal of Neural Transmission

IS - 1

ER -

Effectiveness and tolerability of citalopram for the treatment of depression and anxiety disorders in children and adolescents: An open-label study

Abstract

Bibliographical note

Funding

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this